Leap therapeutics to present updated data from the distinguish study of dkn-01 plus tislelizumab and preclinical data in colorectal cancer models at the sitc annual meeting

Cambridge, mass. , oct. 5, 2022 /prnewswire/ -- leap therapeutics, inc. (nasdaq: lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the company will be presenting updated data from part b of the distinguish study evaluating dkn-01 in combination with tislelizumab, beigene's anti-pd-1 antibody, in second-line gastroesophageal junction/gastric (gej/g) cancer patients whose tumors express high levels of dkk1 (dkk1-high) at the society of immunotherapy for cancer (sitc) 37th annual meeting being held in boston, ma on november 8-12, 2022.
LPTX Ratings Summary
LPTX Quant Ranking